[HTML][HTML] Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets

J Yang, J Xu, W Wang, B Zhang, X Yu… - Signal transduction and …, 2023 - nature.com
Over decades, researchers have focused on the epigenetic control of DNA-templated
processes. Histone modification, DNA methylation, chromatin remodeling, RNA modification …

[HTML][HTML] The role of m6A methylation in therapy resistance in cancer

H Zhuang, B Yu, D Tao, X Xu, Y Xu, J Wang, Y Jiao… - Molecular cancer, 2023 - Springer
Cancer therapy resistance is the main cause of cancer treatment failure. The mechanism of
therapy resistance is a hot topic in epigenetics. As one of the most common RNA …

[HTML][HTML] N6-methyladenosine–mediated up-regulation of FZD10 regulates liver cancer stem cells' properties and lenvatinib resistance through WNT/β-catenin and …

J Wang, H Yu, W Dong, C Zhang, M Hu, W Ma, X Jiang… - Gastroenterology, 2023 - Elsevier
Background & Aims Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-
related deaths worldwide, but there is a deficiency of early diagnosis biomarkers and …

[HTML][HTML] Methyltransferase-like proteins in cancer biology and potential therapeutic targeting

YN Qi, Z Liu, LL Hong, P Li, ZQ Ling - Journal of Hematology & Oncology, 2023 - Springer
RNA modification has recently become a significant process of gene regulation, and the
methyltransferase-like (METTL) family of proteins plays a critical role in RNA modification …

[HTML][HTML] m6A methylation: a process reshaping the tumour immune microenvironment and regulating immune evasion

X Cao, Q Geng, D Fan, Q Wang, X Wang, M Zhang… - Molecular cancer, 2023 - Springer
Abstract N6-methyladenosine (m6A) methylation is the most universal internal modification
in eukaryotic mRNA. With elaborate functions executed by m6A writers, erasers, and …

[HTML][HTML] HNRNPL induced circFAM13B increased bladder cancer immunotherapy sensitivity via inhibiting glycolysis through IGF2BP1/PKM2 pathway

J Lv, K Li, H Yu, J Han, J Zhuang, R Yu… - Journal of Experimental …, 2023 - Springer
Background The response rate to immunotherapy in patients with bladder cancer (BCa)
remains relatively low. Considering the stable existence and important functions in tumour …

METTL3 from target validation to the first small-molecule inhibitors: a medicinal chemistry journey

F Fiorentino, M Menna, D Rotili… - Journal of Medicinal …, 2023 - ACS Publications
RNA methylation is a critical mechanism for regulating the transcription and translation of
specific sequences or for eliminating unnecessary sequences during RNA maturation …

3′ UTR heterogeneity and cancer progression

JJ Chan, H Tabatabaeian, Y Tay - Trends in Cell Biology, 2023 - cell.com
The majority of human mRNAs generate alternative 3′ untranslated regions (UTRs)
through various processes, including RNA modifications such as RNA editing, m 6 A …

Targeting METTL3 reprograms the tumor microenvironment to improve cancer immunotherapy

H Yu, J Liu, X Bu, Z Ma, Y Yao, J Li, T Zhang… - Cell Chemical …, 2024 - cell.com
The tumor microenvironment (TME) is a heterogeneous ecosystem containing cancer cells,
immune cells, stromal cells, cytokines, and chemokines which together govern tumor …

METTL3 inhibition induced by M2 macrophage-derived extracellular vesicles drives anti-PD-1 therapy resistance via M6A-CD70-mediated immune suppression in …

J Ning, X Hou, J Hao, W Zhang, Y Shi… - Cell Death & …, 2023 - nature.com
The treatment options for advanced papillary thyroid cancer (PTC) and anaplastic thyroid
cancer (ATC) refractory to standard therapies are limited. Although anti-PD-1 therapy has a …